Selpercatinib (Retevmo)

RET (Rearranged During Transfection) Kinase Inhibitor

MECHANISM OF ACTION

MECHANISM OF KIDNEY INJURY

Inhibition of active tubular secretion of creatinine without clinically meaningful alteration in renal function.

CLINICAL KIDNEY SYNDROME

Elevation in serum creatinine

CARDIOVASCULAR ADVERSE EFFECTS

LYTE ABNORMALITIES

14% and 47% increase in serum creatinine has been reported.

RISK FACTORS

MITIGATION STRATEGIES

SUGGESTIONS

NOTES/COMMENTS

PHARMACOKINETICS

Molecular Weight

Volume of Distribution

Plasma Protein Binding

Metabolism

Bioavailability

Half-life elimination

Time to peak

Excretion

Dialyzable?

REF:

Izzedine, H., Bouderlique, E., & Besse, B. (2024). Selpercatinib and pseudo-decreases in kidney function. New England Journal of Medicine, 390(13), 1241-1243. https://doi.org/10.1056/nejmc2400216

PATHOLOGY SLIDES:

ENTRY UPDATES:

Mohamed Ibrahim

USA

Nov 19, 2024

PARTNERS WITH